ValuEngine cut shares of Minerva Neurosciences (NASDAQ:NERV) from a sell rating to a strong sell rating in a research report sent to investors on Sunday.
Separately, Zacks Investment Research lowered shares of Minerva Neurosciences from a buy rating to a hold rating in a report on Thursday, October 5th. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. Minerva Neurosciences presently has an average rating of Hold and a consensus target price of $13.94.
Minerva Neurosciences (NERV) traded down $0.10 during trading on Friday, reaching $6.05. 229,199 shares of the company traded hands, compared to its average volume of 159,550. The stock has a market cap of $234.14, a price-to-earnings ratio of -5.45 and a beta of 1.53. Minerva Neurosciences has a one year low of $4.80 and a one year high of $12.60.
In related news, CFO Geoff Race sold 5,829 shares of the stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $5.79, for a total value of $33,749.91. Following the completion of the sale, the chief financial officer now directly owns 197,698 shares of the company’s stock, valued at approximately $1,144,671.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 12,590 shares of company stock valued at $73,073 over the last three months. 21.60% of the stock is currently owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in NERV. Nationwide Fund Advisors grew its holdings in Minerva Neurosciences by 14.2% during the 2nd quarter. Nationwide Fund Advisors now owns 13,005 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 1,616 shares in the last quarter. Russell Investments Group Ltd. grew its holdings in Minerva Neurosciences by 54.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 15,794 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 5,579 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Minerva Neurosciences during the 2nd quarter valued at approximately $145,000. State of Wisconsin Investment Board purchased a new stake in Minerva Neurosciences during the 2nd quarter valued at approximately $159,000. Finally, ProShare Advisors LLC grew its holdings in Minerva Neurosciences by 1.4% during the 2nd quarter. ProShare Advisors LLC now owns 21,063 shares of the biopharmaceutical company’s stock valued at $186,000 after buying an additional 297 shares in the last quarter. 73.68% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3125842/minerva-neurosciences-nerv-lowered-to-strong-sell-at-valuengine.html.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.